<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1463">
  <stage>Registered</stage>
  <submitdate>15/07/2006</submitdate>
  <approvaldate>17/10/2006</approvaldate>
  <actrnumber>ACTRN12606000444583</actrnumber>
  <trial_identification>
    <studytitle>Polidocanol sclerotherapy of pharyngx for obstructive sleep apnea (OSA) and snoring subjects(SS)</studytitle>
    <scientifictitle>Preliminary study on submucosous sclerosis of pharyngx with 1% polidocanol to treat obstructive sleep apnea (OSA) &amp; snoring subjects (SS)</scientifictitle>
    <utrn />
    <trialacronym>PSP-osas &amp; ss</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Obstructive sleep apnea syndrome (OSAS)</healthcondition>
    <healthcondition>Snoring subjects (SS)</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Sleep apnoea</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Polysomnography (PSG) and 1% Polidocanol--submucosous sclerosis in the part of pharyngx with 1% polidocanol injection
The duration : about 4~5 years
Each patient with OSAS will be followed up 2 years after treatment.
The injection administered is during the treatment, the injection should be in the retrophargngeal submucosa and lateral pharyngeal bands and lateral pharyngeal submucosa and in front submucosa of soft palate.  The injection is multi-point, and each point injection is 0.3~0.5ml, the total quantity/each time is not more than 5ml; Every patient have to be treated about 1~2 times.
-------The duration of the study is 4~5 years.the treatment is only during 1~3 months.The follow-up-2-year is carried on polysomnography and clinical study-observarion.</interventions>
    <comparator>No comparator.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Apnea-hypopnea index (AHI) in 2 years.

AHI is on polysomnography (PSG), to compare AHI anterior (1 time) and posterior treatment (3 times).</outcome>
      <timepoint>Each patient with osas must be carried out PSG for 4 times.One time is before treatment, the others times are in 1/2, 1 and 2 years after treatment.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Anterior-posterior treatment in 2 years.

AHI is on polysomnography (PSG), to compare AHI anterior (1 time) and posterior treatment (3 times).</outcome>
      <timepoint>Each patient with osas must be carried out PSG for 4 times.One time is before treatment, the others times are in 1/2, 1 and 2 years after treatment.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Arterial oxygen saturation (SaO2) and body mass index (BMI) will be measured on polysomnography (PSG), to compare the lowest SaO2 of anterior - posterior treatment and variation of BMI.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>OSAS &amp; ,SS which palatopharyngeal collapse.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Obstructive sleep apnea syndrom (OSAS)  &amp;  snoring subjects (SS),which anatomic narrow result.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate>1/12/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>China</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Youliang Yin</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Liaoyang central Hospital</fundingname>
      <fundingaddress />
      <fundingcountry>China</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Liaoyang Central Hospital</sponsorname>
      <sponsoraddress />
      <sponsorcountry>China</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of this prospective study is to evaluate the results of polidocanol sclerotherapy of pharynx for OSAS &amp; SS,to reduce pharyngeal compliance.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Liaoyang Central hospital ethics committee</ethicname>
      <ethicaddress>Liaoning Liaoyang Zhonghua Street No.148 Post code:111000</ethicaddress>
      <ethicapprovaldate>28/06/2006</ethicapprovaldate>
      <hrec>06002</hrec>
      <ethicsubmitdate />
      <ethiccountry>China</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Youliang Yin</name>
      <address>Ear-Nose-Throat Department
Liaoning Liaoyang Central Hospital
No.148 Zhonghua Street
111000 China</address>
      <phone>0419 3220220 &amp; 3220627</phone>
      <fax />
      <email>you201211@yahoo.com.cn and light2006211@hotmail.com</email>
      <country>China</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Hongyan Chen</name>
      <address>Emergency Department
Liaoyang Central Hospital
No.148 Zhonghua Street 
Liaoyang Liaoning of PRC
111000 </address>
      <phone>0419 3221423</phone>
      <fax />
      <email>lychy2006@yahoo.com.cn and hongyan200628@hotmail.com</email>
      <country>China</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>